Phase 2 Trial

The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the development of vilobelimab for COVID-19 patients. The grant was awarded as part of a government initiative, which the German...

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related: Atea Unveils Trial Amendments, New Data For COVID-19 Program. The trial did not meet the primary...

BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects.  A statistically significant improvement from baseline was observed in the appearance of acne-prone skin, but no meaningful difference was...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced Day 90 data for the first patient from the Phase 1/2 trial of VX-880 for type 1 diabetes (T1D).  VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy. The...

Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME).  The data were presented at the American Society of Retina Specialists Annual Meeting. RGX-314...

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative colitis (UC). The study did not meet the primary efficacy endpoint of clinical remission at Week 12 nor secondary...

Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally well tolerated for up to 14 days of dosing, with robust distribution in the central nervous system and predictable dose-...

Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis.  The Phase 2 Dose-Ranging study showed clinically significant changes in increases...

Vaxart Inc (NASDAQ: VXRT) has begun recruiting subjects for its Phase 2 COVID-19 oral tablet vaccine clinical trial.  Related: FDA Clears Vaxart's Mid-Stage Trial For S-Only Oral COVID-19 Vaccine Candidate. Vaxart expects to begin dosing the first of 96 subjects, split...

Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin agonist. According to Takeda, TAK 994 was undergoing two Phase 2 trials for narcolepsy Type 1 with cataplexy and...

Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC).  The study achieved the primary objective of safety and tolerability with...

Gemini Therapeutics Inc (NASDAQ: GMTX) announced a corporate restructuring, including several executive officer transitions, prioritizing assets, and focusing on GEM103's pivotal trial in geographic atrophy (GA). The Company will cease research and non-clinical programs, including...

Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function. ANVS401 was well-tolerated and safe, with no adverse...

RedHill Biopharma Ltd (NASDAQ: RDHL) has reported new data from the opaganib global Phase 2/3 study in hospitalized COVID-19 patients with severe pneumonia. Related: What's Happening With RedHill Biopharma's Stock On Tuesday? The data comes from a post-hoc analysis of...

After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements....